Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9

American Journal of Kidney Diseases

Volumn 62, Issue 4, 2013, Pages 796-800

  Van Poelgeest, Eveline P ^a   Swart, Reinout M ^b   Betjes, Michiel G H ^b   Moerland, Matthijs ^a   Weening, Jan J ^b   Tessier, Yann ^c   Hodges, Michael R ^c   Levin, Arthur A ^c   Burggraaf, Jacobus ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Santaris Pharma AS   (Denmark)

Author keywords

Clinical kidney injury; oligonucleotide; PCSK9 (proprotein convertase subtilisin kexin type 9)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA 2 MICROGLOBULIN; CREATININE; GLUTATHIONE TRANSFERASE ALPHA; HYPOCHOLESTEROLEMIC AGENT; KIDNEY INJURY MOLECULE 1; LOCKED NUCLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N ACETYL BETA GLUCOSAMINIDASE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SPC 5001; SUBTILISIN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; BASEMENT MEMBRANE; CASE REPORT; CELL DEATH; CELL VACUOLE; CHOLESTEROL BLOOD LEVEL; CONSERVATIVE TREATMENT; CONVALESCENCE; CREATININE BLOOD LEVEL; CYTOSKELETON; ELECTRON MICROSCOPY; ENDOSOME; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMATURIA; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE TEST; INJECTION SITE REACTION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TUBULE FUNCTION; KIDNEY TUBULE NECROSIS; LEUKOCYTE; PHAGOLYSOSOME;

CLINICAL KIDNEY INJURY; OLIGONUCLEOTIDE; PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9);

ACUTE KIDNEY INJURY; FEMALE; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84884534231     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.02.359     Document Type: Article

References (37)

1. C.F. Bennett, E.E. Swayze RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform Annu Rev Pharmacol Toxicol 50 2010 259 293
2. G. Lippi, E.J. Favaloro Antisense therapy in the treatment of hypercholesterolemia Eur J Intern Med 22 6 2011 541 546
3. E.R. Rayburn, R. Zhang Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 13 11-12 2008 513 521
4. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr, H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 12 2006 1264 1272
5. Y. Luo, L. Warren, D. Xia Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice J Lipid Res 50 8 2009 1581 1588
6. B. Cariou, M.C. Le, P. Costet Clinical aspects of PCSK9 Atherosclerosis 216 2 2011 258 265
7. G. Lambert, M. Krempf, P. Costet PCSK9: a promising therapeutic target for dyslipidemias? Trends Endocrinol Metab 17 3 2006 79 81
8. G. Tibolla, G.D. Norata, R. Artali, F. Meneghetti, A.L. Catapano Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition Nutr Metab Cardiovasc Dis 21 11 2011 835 843
9. J.D. Horton, J.C. Cohen, H.H. Hobbs Molecular biology of PCSK9: its role in LDL metabolism Trends Biochem Sci 32 2 2007 71 77
10. A.C. Fahed, G.M. Nemer Familial hypercholesterolemia: the lipids or the genes? Nutr Metab (Lond) 8 1 2011 23
11. B. Sjouke, D.M. Kusters, J.J. Kastelein, G.K. Hovingh Familial hypercholesterolemia: present and future management Curr Cardiol Rep 13 6 2011 527 536
12. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 6 1999 461 470
13. S.P. Henry, M.V. Templin, N. Gillett, J. Rojko, A.A. Levin Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1 Toxicol Pathol 27 1 1999 95 100
14. M. Butler, K. Stecker, C.F. Bennett Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues Lab Invest 77 4 1997 379 388
15. J.V. Bonventre, V.S. Vaidya, R. Schmouder, P. Feig, F. Dieterle Next-generation biomarkers for detecting kidney toxicity Nat Biotechnol 28 5 2010 436 440
16. M.A. Perazella, S.G. Coca Traditional urinary biomarkers in the assessment of hospital-acquired AKI Clin J Am Soc Nephrol 7 1 2012 167 174
17. S.P. Henry, M. Johnson, T.A. Zanardi Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey Toxicology 301 1-3 2012 13 20
18. F.M. van de Water, O.C. Boerman, A.C. Wouterse, J.G. Peters, F.G. Russel, R. Masereeuw Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules Drug Metab Dispos 34 8 2006 1393 1397
19. M.W. Lindholm, J. Elmen, N. Fisker PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates Mol Ther 20 2 2012 376 381
20. D.K. Monteith, M.J. Horner, N.A. Gillett Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys Toxicol Pathol 27 3 1999 307 317
21. M. Lindow, S. Kauppinen Discovering the first microRNA-targeted drug J Cell Biol 199 3 2012 407 412
22. S.P. Henry, H. Bolte, C. Auletta, D.J. Kornbrust Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys Toxicology 120 2 1997 145 155
23. S.K. Srinivasan, P. Iversen Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides J Clin Lab Anal 9 2 1995 129 137
24. U.M. Sarmiento, J.R. Perez, J.M. Becker, R. Narayanan In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice Antisense Res Dev 4 2 1994 99 107
25. M.A. Ferguson, V.S. Vaidya, J.V. Bonventre Biomarkers of nephrotoxic acute kidney injury Toxicology 245 3 2008 182 193
26. W.G. Herrington, D.C. Talbot, M.M. Lahn Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma Am J Kidney Dis 57 2 2011 300 303
27. N.G. Seidah, G. Mayer, A. Zaid The activation and physiological functions of the proprotein convertases Int J Biochem Cell Biol 40 6-7 2008 1111 1125
28. N. Ferri, G. Tibolla, A. Pirillo Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels Atherosclerosis 220 2 2012 381 386
29. K.R. Feingold, A.H. Moser, J.K. Shigenaga, S.M. Patzek, C. Grunfeld Inflammation stimulates the expression of PCSK9 Biochem Biophys Res Commun 374 2 2008 341 344
30. Y. Fujiwara, H. Tsuchiya, N. Sakai, K. Shibata, A. Fujimura, T.A. Koshimizu Proximal tubules and podocytes are toxicity targets of bucillamine in a mouse model of drug-induced kidney injury Eur J Pharmacol 670 1 2011 208 215
31. K. Fitzgerald, M. Frank-Kamenetsky, T. Mant Phase I safety, pharmacokinetic, and pharmacodynamic results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia [abstract] Arterioscler Thromb Vasc Biol 32 2012 A67 (suppl 5; meeting abstracts)
32. Z. Zhao, Y. Tuakli-Wosornu, T.A. Lagace Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote Am J Hum Genet 79 3 2006 514 523
33. F. Akdim, E.S. Stroes, E.J. Sijbrands Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 15 2010 1611 1618
34. A.M. Krieg Targeting LDL cholesterol with LNA Mol Ther Nucleic Acids 1 2012 e6
35. M.A. Perazella Toxic nephropathies: core curriculum 2010 Am J Kidney Dis 55 2 2010 399 409
36. I.E. Hall, S.G. Coca, M.A. Perazella Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis Clin J Am Soc Nephrol 6 12 2011 2740 2749
37. W.S. Waring, A. Moonie Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury Clin Toxicol (Phila) 49 8 2011 720 728